Thus, a combined therapy aimed at inhibiting PDE5 and PDE4 enzymes (especially some isoforms, such as PDE4D) could be more effective in ameliorating cognitive deficits in AD patients, as already shown in aged rodents [87]. This evidence concerns the gene PDE5A and Alzheimer disease.